Claude  Maraoui net worth and biography

Claude Maraoui Biography and Net Worth

Co-Founder, President & Chief Executive Officer of Journey Medical

Claude has more than 30 years of experience in commercializing some of the most successful dermatology products in the world. He served as Vice President of Dermatology Sales at Medicis Pharmaceutical Corporation and has held various leadership positions in marketing and sales for therapeutic and aesthetic dermatology. He has executed more than 50 product launches during his career. In 2012, Valeant Pharmaceuticals International Inc. acquired Medicis for approximately $2.6B. Claude received his B.S. in Business and Marketing from Rutgers University.

What is Claude Maraoui's net worth?

The estimated net worth of Claude Maraoui is at least $16.65 million as of May 2nd, 2025. Mr. Maraoui owns 2,348,313 shares of Journey Medical stock worth more than $16,649,539 as of July 20th. This net worth evaluation does not reflect any other investments that Mr. Maraoui may own. Learn More about Claude Maraoui's net worth.

How do I contact Claude Maraoui?

The corporate mailing address for Mr. Maraoui and other Journey Medical executives is 9237 East Via de Ventura Boulevard, Suite 105, Scottsdale, AZ 85258, United States. Journey Medical can also be reached via phone at 480-434-6670 and via email at [email protected]. Learn More on Claude Maraoui's contact information.

Has Claude Maraoui been buying or selling shares of Journey Medical?

Claude Maraoui has not been actively trading shares of Journey Medical over the course of the past ninety days. Most recently, Claude Maraoui sold 4,834 shares of the business's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $6.84, for a transaction totalling $33,064.56. Following the completion of the sale, the chief executive officer now directly owns 2,348,313 shares of the company's stock, valued at $16,062,460.92. Learn More on Claude Maraoui's trading history.

Who are Journey Medical's active insiders?

Journey Medical's insider roster includes Ramsey Alloush (Chief Operating Officer & General Counsel), and Claude Maraoui (Co-Founder, President & Chief Executive Officer). Learn More on Journey Medical's active insiders.

Claude Maraoui Insider Trading History at Journey Medical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/2/2025Sell4,834$6.84$33,064.562,348,313View SEC Filing Icon  
3/11/2025Sell49,271$5.01$246,847.712,003,147View SEC Filing Icon  
3/7/2025Sell14,905$5.01$74,674.052,052,418View SEC Filing Icon  
3/5/2025Sell18,147$5.13$93,094.112,092,874View SEC Filing Icon  
3/3/2025Sell23,508$5.19$122,006.522,139,922View SEC Filing Icon  
3/22/2024Buy10,000$3.48$34,800.002,163,430View SEC Filing Icon  
See Full Table

Claude Maraoui Buying and Selling Activity at Journey Medical

This chart shows Claude Maraoui's buying and selling at Journey Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Journey Medical Company Overview

Journey Medical logo
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Read More

Today's Range

Now: $7.09
Low: $7.03
High: $7.26

50 Day Range

MA: $6.43
Low: $5.01
High: $7.27

2 Week Range

Now: $7.09
Low: $4.31
High: $9.56

Volume

172,035 shs

Average Volume

313,799 shs

Market Capitalization

$195.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07